Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: Implications for the inhibition of factor Xa, tPA, and urokinase

Journal of Medicinal Chemistry

Volumn 41, Issue 27, 1998, Pages 5445-5456

  Stubbs, Milton T ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; PROTEIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UROKINASE;

ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; NONHUMAN; PROTEIN PURIFICATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZAMIDINES; BINDING SITES; CATTLE; CRYSTALLOGRAPHY, X-RAY; FACTOR XA; HUMANS; MODELS, MOLECULAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; TRYPSIN INHIBITORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032585544     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981068g     Document Type: Article

References (42)

1. α-tosyl-3-amidino-D,L-phenylalanine-piperidide; TIPPS, 2,4,6-triisopropylphenylsulfonyl; rms, root-mean-square.
2. Harker, L. A.; Hanson, S. R.; Kelly, A. B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb. Haemost. 1997, 78, 736-741.
3. Andreasen, P. A.; Kjoller, L.; Christensen, L.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis - A review. Int. J. Cancer 1997, 72, 1-22.
4. Rabbani, S. A.; Xing, R. H. M. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 1998, 12, 911-920.
5. α-arylsulfonylaminoacylated 4-amidinophenylalanine -tight binding inhibitors of thrombin. Thromb. Res. 1983, 29, 635-642.
6. Stürzebecher, J.; Stürzebecher, U.; Vieweg, H.; Wagner, G.; Hauptmann, J.; Markwardt, F. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency. Thromb. Res. 1989, 54, 245-252.
7. Stürzebecher, J.; Prasa, D.; Wikström, P.; Vieweg, H. Structureactivity relationships of inhibitors derived from 3-amidinophenylalanine. J. Enzyme Inhib. 1995, 9, 87-99.
8. Stürzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikström, P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 1997, 40, 3091-3099.
9. Stürzebecher, J.; Markwardt, F.; Wagner, G.; Walsmann, P. Synthetische Hemmstoffe der Serinproteasen. 13. Quantitative Struktur-Wirkungs-Beziehungen bei der Hemmung von Trypsin, Plasmin und Thrombin durch 4-Amidinophenylverbindungen mit Ketonstruktur. [Synthetic inhibitors of serine proteinases. 13. Quantitative structure-activity relationship for inhibition of trypsin and thrombin by 4-amidinophenyl compounds with a ketone structure.] Acta Blol. Med. Ger. 1976, 35, 1665-1676.
10. Bode, W.; Mayr, L; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467-3475.
11. Stubbs, M. T.; Bode, W. Crystal structures of thrombin and thrombin complexes as a framework for antithrombotic drug design. Perspect. Drug Discovery Des. 1993, 7, 431-452.
12. Bode, W.; Turk, D.; Stürzebecher, J. Geometry of binding of the benzamioUne- and arginine-based inhibitors NAPAP and MQPA to human a-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur. J. Biochem. 1990, 193, 175-182.
13. Turk, D.; Stürzebecher, J.; Bode, W. Geometry of binding of the Na-tosylated piperidides of m-amidino, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes. FEBS Lett. 1991,287, 133-138.
14. Banner, D. W.; Hadvary, P. Crystallographic analysis at 3.0 A resolution of the binding to human thrombin of four active sitedirected inhibitors. J. Biol. Chem. 1991, 266, 20085-20093.
15. Brandstetter, H.; Turk, D.; Hoeffken, H. W.; Grosse, D.; Stürzebecher, J.;.Martin, P. D.; Edwards, B. F.; Bode, W. Refined 2.3 Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J. Mol. Biol. 1992,226,1085-1099.
16. Padmanabhan, K.; Padmanabhah, K. P.; Tulinsky, A.; Park, C.; H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of human des(l-45) factor Xa at 2.2 A resolution. J. Mol. Biol. 1993, 232, 947-966.
17. Lamba, D.; Bauer, M.; Huber, R.; Fischer, S.; Rudolph, R.; Kohnert, U.; Bode, W. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J. Mol. Biol. 1996, 258, 117-135.
18. Spraggon, G.; Phillips, C.; Nowak, U.K.; Ponting, C. P.; Saunders: D.; Dobson, C. M.; Stuart, D. I.; Jones, E. Y. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995, 3, 681-691.
19. Stubbs, M. T. Structural aspects of Factor Xa Inhibition. Curr. Pharm. Des. 1996, 2, 543-552.
20. Stubbs, M. T.; Huber, R.; Bode, W. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. FEES Lett. 1995, 375, 103-107.
21. Brandstetter, H.; Kühne, A.; Bode, W.; Huber, R.; von der Saal, W.; Wirthensohn, K.; Engh, R. A. X-ray structure of active siteinhibited clotting factor Xa. Implications for drug design and substrate recognition. J. Biol. Chem. 1996, 271, 29988-29992.
22. Schroeder, D. D.; Shaw, E. Chromatography of trypsin and its derivatives. Characterization of a new active form of bovine trypsin. J. Biol. Chem. 1968, 243, 2943-2949.
23. Leslie, A. G. W. Mosflm user guide, Mosflm version 5.20; MRC Laboratory of Molecular Biology: Cambridge, U.K., 1994.
24. Kabsch, W. Automatic indexing of rotation diffraction patterns. J. Appl. Crystallogr. 1988, 21, 67-71.
25. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
26. To distinguish the various structures, each inhibitor is described by the compound number given in Figure 1, together with a capital letter suffix for the space group as given in Table 2.
27. Briinger, A. X-PLOR (Version 3.1). A System for X-ray Crystallography and NMR; Yale University Press: New Haven, CT, 1992.
28. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeelgaard, M. Improved methods for building protein models in electron density maps and location of errors in these models. Acta Crystallogr. 1991, 47, 110-119.
29. Luzzati, P. V. Traitement statistique des erreurs dans la détermination des structures cristallines. [A statistical treatment of errors in crystallographic structure determination.] Acta Crystallogr. 1952, 5, 802-810.
30. Katz, B. A.; Clark, J. M.; Finer-Moore, J. S.; Jenkins, T. E.; Johnson, C. R.; Ross, M. J.; Luong, C.; Moore, W. R.; Stroud, R. M. Design of potent selective zinc-mediated serine proteinase inhibitors. Nature 1998, 391, 608-612.
31. Renatus, M.; Bode, W.; Huber, R.; Stürzebecher, J.; Prasa, D.; Fischer, S.; Kohnert, U.; Stubbs, M. T. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. J. Biol. Chem. 1997,272,21713-21719.
32. Shaw, K. J.; Guilford, W. J.; Dallas, J. L.; Koovakkaat, S. K.; McCarrick, M. A.; Liang, A.; Light, D. R.; Morrissey, M. M. (Z,Z)2,7-bis(4-amidinobenzylidene)cycloheptan-l-one: Identification of a highly active inhibitor of blood coagulation Factor Xa. J. Med. Chem. 1998, 41, 3551-3556.
33. Maduskie, T. P. Jr.; McNamara, K. J.; Ru, Y.; Knabb, R. M.; Stouten, P. F. W. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J. Med. Chem. 1998, 41, 53-62.
34. Klein, S. I.; Czekaj, M.; Gardner, C. G.; Guertin, K R.; Cheney, D. L.; Spada, A. P.; Bolton, S. A.; Brown, K.; Colussi, D.; Heran, C. L.; Morgan, S. R.; Leadley, R. J.; Dunwiddie, C. T.; Perrone, M. H.; Chu, V. Identification and initial structure-activity relationships of a novel class of non peptide inhibitors of blood coagulation factor Xa. J. Med. Chem. 1998,41, 437-450.
35. Stürzebecher, J.; Markwardt, F. Synthesizche Inhibitoren der Serinproteinasen. 17. Einfluss von Benzamidinderivaten auf die Aktivität der Urokinase und den Ablauf der Fibrinolyse. [Synthetic inhibitors of serine proteinases. 17. The effect of benzamidine derivatives on the activity of urokinase and the reduction of fibrinolysis.] Pharmazie 1978, 33, 599-602.
36. Towle, M. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E.; Bridges, A. J.; Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo[6]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor. Cancer Res. 1993,53, 2553-2559.
37. Yang, H.; Henkin, J.; Kim, K. H.; Gréer, J. Selective inhibition of urokinase by substituted phenylguanidines: Quantitative Structure-Activity relationship analyses. J. Med. Chem. 1990, 33, 2'956-2961.
38. von der Saal, W.; Engh, R. A.; Eichinger, A.; Kucznierz, R.; Sauer, J. Syntheses and selective inhibitory activities of terphenyl-bisamidines for serine proteases. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 73-82.
39. Stubbs, M. T.; Morenweiser, R.; Stürzebecher, J.; Bauer, M.; Bode, W.; Huber, R.; Piechottka, G. P.; Matschiner, G.; Sommerhoff, C. P.; Fritz, H.; Auerswald, E. A. The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin: Implications for the structure and function of human mast cell tryptase and its inhibition. J. Biol. Chem. 1997, 272, 19931-19937.
40. Gabriel, B.; Stubbs, M. T.; Bergner, A.; Hauptmann, J.; Bode, W.; Stürzebecher, J.; Moroder, L. Structure-based design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 1998, 41, 4240-4250.
41. Figure prepared using the program MAIN (Turk, D. Weiterentwicklung eines Programmes für Molekülgraphik und Elektronendichte-Manipulation und seine Anwendung auf verschiedene Protein-Strukturaufklärungen. Ph.D. Thesis, Technische Universität München, 1992).
42. Figure prepared using the program MOLSCRIPT (Kraulis, P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950).